Summary of the values of maximal active force, pCa50 and nH before and after PKA treatment in PLV after reconstitution with cTn or PCRF or treatment with PP1
| Maximal force (mN/mm2) | pCa50 | nH | |
| Fig. 2 C | |||
| Control PLV | 55.99 ± 5.92 | 5.55 ± 0.01 | 4.23 ± 0.25 |
| cTn | 52.52 ± 5.48 | 5.62 ± 0.01a | 4.15 ± 0.35 |
| cTn+PKA | 51.17 ± 5.42 | 5.46 ± 0.01ab | 4.56 ± 0.30 |
| Fig. 2 D | |||
| Control PLV | 53.85 ± 6.03 | 5.55 ± 0.02 | 4.16 ± 0.16 |
| PCRF | 51.42 ± 5.35 | 5.64 ± 0.03a | 3.69 ± 0.16 |
| PCRF + PKA | 49.86 ± 5.32 | 5.46 ± 0.01ab | 3.92 ± 0.18 |
| Fig. 3 B | |||
| Control PLV | 59.32 ± 4.51 | 5.55 ± 0.01 | 4.12 ± 0.16 |
| PP1 | 56.47 ± 5.70 | 5.64 ± 0.02a | 4.24 ± 0.35 |
| PP1 + PKA | 54.10 ± 5.66 | 5.46 ± 0.01ab | 4.05 ± 0.20 |
| Maximal force (mN/mm2) | pCa50 | nH | |
| Fig. 2 C | |||
| Control PLV | 55.99 ± 5.92 | 5.55 ± 0.01 | 4.23 ± 0.25 |
| cTn | 52.52 ± 5.48 | 5.62 ± 0.01a | 4.15 ± 0.35 |
| cTn+PKA | 51.17 ± 5.42 | 5.46 ± 0.01ab | 4.56 ± 0.30 |
| Fig. 2 D | |||
| Control PLV | 53.85 ± 6.03 | 5.55 ± 0.02 | 4.16 ± 0.16 |
| PCRF | 51.42 ± 5.35 | 5.64 ± 0.03a | 3.69 ± 0.16 |
| PCRF + PKA | 49.86 ± 5.32 | 5.46 ± 0.01ab | 3.92 ± 0.18 |
| Fig. 3 B | |||
| Control PLV | 59.32 ± 4.51 | 5.55 ± 0.01 | 4.12 ± 0.16 |
| PP1 | 56.47 ± 5.70 | 5.64 ± 0.02a | 4.24 ± 0.35 |
| PP1 + PKA | 54.10 ± 5.66 | 5.46 ± 0.01ab | 4.05 ± 0.20 |
Maximal force was obtained by activating muscle at pCa 4.5 before plotting of the force-pCa curve at each condition.
P < 0.05 compared with the corresponding values for control PLV (before thin filament reconstitution or PP1 treatment).
P < 0.05 compared with the corresponding values for thin filament reconstitution or PP1 treatment (before PKA treatment).